Fulltext

Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine plus Saquinavir or Zidovudine and Zalcitabine plus Saquinavir in AIDS Clinical Trials Group 229

Schapiro, Jonathan M. ; Lawrence, Jody ; Speck, Roberto ; Winters, Mark A. ; Efron, Bradley ; Coombs, Robert W. ; Collier, Ann C. ; Merigan, Thomas C.

In: The Journal of Infectious Diseases, 1999, vol. 179, no. 1, p. 249-253

Ajouter à la liste personnelle
    Titre
    • Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine plus Saquinavir or Zidovudine and Zalcitabine plus Saquinavir in AIDS Clinical Trials Group 229
    Auteur
    • Schapiro, Jonathan M.. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Lawrence, Jody. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Speck, Roberto. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Winters, Mark A.. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Efron, Bradley. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Coombs, Robert W.. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Collier, Ann C.. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    • Merigan, Thomas C.. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, Seattle, Washington, Geneva, California, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The Journal of Infectious Diseases, 1999, vol. 179, no. 1, p. 249-253. University Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:304552
    Summary
    The relationships among treatment regimens, plasma human immunodeficiency virus (HIV) RNA levels, and resistance mutations to saquinavir (codons 48 and 90) and zidovudine (codon 215) were examined in a cohort of 144 patients from the AIDS Clinical Trials Group 229 study. After 24-40 weeks of therapy, no patients who had received the two-drug combination (zidovudine plus saquinavir) had only codon 48 mutations, 45.8% had only codon 90 mutations, and 8.3% had both codon 48 and 90 mutations. Mutations developed by patients who had received the three-drug combination (zidovudine and zalcitabine plus saquinavir) were codon 48 alone in 1.4%, codon 90 alone in 33.3%, and both codons 48 and 90 in 4.2%. The difference between the groups showed a trend toward reduced mutations with three versus two drugs but did not reach significance (p = .11, two-sided χ2). Higher baseline HIV RNA levels correlated with the development of protease mutations. Mutations at codon 215 were present in 82% of all patients at baseline and in 87% after therapy